Clinical utility of a protein-based oncopanel in patients with end-stage head and neck cancer

Tools

Item Type:	Article
Title:	Clinical utility of a protein-based oncopanel in patients with end-stage head and neck cancer
Creators Name:	Doescher, J., Weissinger, S.E., Schönsteiner, S.S., Lisson, C., Bullinger, L., Barth, T.F., Leithäuser, F., Mueller-Richter, U., Laban, S., Hoffmann, T.K., Möller, P., Lennerz, J.K. and Schuler, P.J.
Abstract:	In a prospective clinical initiative, we selected heavily pretreated head and neck carcinoma patients and assessed the clinical utility of a protein-based oncopanel for identification of potential targetable markers. Tumor samples of 45 patients were evaluated using a 12-marker immunohistochemistry panel. The primary end point was the prevalence of potentially actionable markers. At least one expressed marker in each case could be identified. We noted a high prevalence of EGFR (80%, 39/45) and MET (57.4%, 28/45). Three patients received oncopanel-based therapy with variable results. Despite the limited number of treated subjects, oncopanel analysis in end-stage head and neck cancer is operationally and technically feasible. Combination with targeted next generation sequencing might provide additional therapy options.
Keywords:	Crizotinib, Decision Making, Head and Neck Cancer, Imatinib Mesylate, Immunohistochemistry, Oncopanel, Precision Oncology, Trastuzumab
Source:	Immunotherapy
ISSN:	1750-7448
Publisher:	Future Medicine
Volume:	11
Number:	14
Page Range:	1193-1203
Date:	October 2019
Official Publication:	https://doi.org/10.2217/imt-2019-0041
PubMed:	View item in PubMed

Repository Staff Only: item control page